default author photo

Matthew B. Laurens

University of Maryland, Baltimore (UMB) - School of Medicine

Baltimore, MD

United States

University of Maryland, Baltimore (UMB)

620 W. Lexington St.

Baltimore, MD 21201

United States

- Center for Vaccine Development and Global Health

685 W. Baltimore St

Room 480

Baltimore, MD 21201

United States

- Department of Pediatrics

  • University of Maryland, Baltimore (UMB) - School of Medicine

  • University of Maryland, Baltimore (UMB)

  • - Center for Vaccine Development and Global Health

SCHOLARLY PAPERS

6

DOWNLOADS

740

TOTAL CITATIONS

2

Scholarly Papers (6)

Actions:
Email selected abstracts
1.

Risk of COVID-19 after Natural Infection or Vaccination

Number of pages: 24 Posted: 01 May 2023
Anne-Marie Rick, Matthew B. Laurens, Ying Huang, HVTN 097 Protocol Leadership Team, Chenchen Yu, Thomas C. S. Martin, Carina A. Rodriguez, Christina Rostad, Rebone M. Maboa, Lindsey Baden, Hana M. El Sahly, Beatriz Grinsztejn, Glenda Gray, Cynthia L. Gay, Peter B. Gilbert, Holly E. Janes, James G. Kublin, Yunda Huang, Brett Leav, Ian Hirsch, Frank Struyf, Lisa M. Dunkle, Kathleen M. Neuzil, Lawrence Corey, Paul Goepfert, Stephen R. Walsh, Dean Follmann and Karen L. Kotloff
University of Pittsburgh - Department of Pediatrics, University of Maryland, Baltimore (UMB) - School of Medicine, Fred Hutchinson Cancer Research Center, affiliation not provided to SSRN, Fred Hutchinson Cancer Research Center, University of California, San Diego (UCSD) - Division of Infectious Diseases and Global Public Health, University of South Florida - Morsani College of Medicine, Emory University School of Medicine and Children’s Healthcare of Atlanta - Department of Pediatrics, Ndlovu Research Centre, Harvard University - Brigham and Women’s Hospital, Baylor College of Medicine, Instituto Nacional de Infectologia Evandro Chagas, Fiocruz - Lab. De Pesquisa Clinica DST/AIDS, South African Medical Research Council, University of North Carolina (UNC) at Chapel Hill - School of Medicine, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Moderna, Inc., AstraZeneca Pharmaceuticals, Janssen Research & Development, LLC, Novavax, Inc., - Center for Vaccine Development and Global Health, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, University of Alabama at Birmingham - Heersink School of Medicine, Harvard University - Brigham and Women’s Hospital, Government of the United States of America - Biostatistics Research Branch and - Department of Pediatrics
Downloads 228 (334,744)

Abstract:

Loading...

COVID-19, natural infection, hybrid immunity, vaccination

2.

Dose-Escalation, Double-Blind, Placebo-Controlled Evaluation of MAM01 Human Monoclonal Antibody for Protection Against Malaria: A First-in-Human, Phase 1 Adaptive Trial

Number of pages: 25 Posted: 23 Jun 2025
Kirsten E. Lyke, Andrea A. Berry, Matthew B. Laurens, Jennifer Winkler, Sudhaunshu Joshi, Abra Rachida Koudjra, Lauryn Butler, Peter F. Billingsley, Tales Pascini, Asha Patil, Kim Lee B. Sim, Grace Fitzgerald, Julie Riegel, Kayla Andrews, Micha Levi, Aparna Anderson, Charles Wells, Hong Liu, James Huleatt and R. Scott Miller
University of Maryland, Baltimore (UMB), - Center for Vaccine Development and Global Health, University of Maryland, Baltimore (UMB) - School of Medicine, affiliation not provided to SSRN, University of Maryland, Baltimore (UMB), University of Maryland, Baltimore (UMB), University of Maryland, Baltimore (UMB), Sanaria Inc, Sanaria Inc, Sanaria Inc, Sanaria Inc, Gates Medical Research Institute, Gates Medical Research Institute, Gates Medical Research Institute, Gates Medical Research Institute, Gates Medical Research Institute, Gates Medical Research Institute, Gates Medical Research Institute, Gates Medical Research Institute and Gates Medical Research Institute
Downloads 200 (380,469)

Abstract:

Loading...

Malaria, Monoclonal antibody, Plasmodium falciparum, Circumsporozoite Protein, Repeat region, MAM01, Phase 1 trial, Subcutaneous, Intravenous

3.

Efficacy of Typhoid Conjugate Vaccine: Final Analysis of a Four-Year, Randomised Controlled Trial in Malawian Children

Number of pages: 19 Posted: 07 Apr 2023
Priyanka D. Patel, Yuanyuan Liang, James E. Meiring, Nedson Chasweka, Pratiksha Patel, Theresa Misiri, Felistas Mwakisighile, Richard Wachepa, Happy C. Banda, Florence Shumba, Gift Kawalazira, Queen Dube, Nginache Nampota-Nkomba, Osward M. Nyirenda, Tsion Girmay, Shrimati Datta, Leslie P. Jamka, J. Kathleen Tracy, Matthew B. Laurens, Robert S. Heyderman, Kathleen M. Neuzil and Melita A. Gordon
University of Malawi - Malawi-Liverpool-Wellcome Trust Clinical Research Programme, - Department of Epidemiology and Public Health, University of Sheffield - Department of Infection, Immunity & Cardiovascular Disease, University of Malawi - Malawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi - Malawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi - Malawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi - Malawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi - Malawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi - Malawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi - Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre District Council - District Health Office, Queen Elizabeth Central Hospital, Kamuzu University of Health Sciences - Blantyre Malaria Project, Kamuzu University of Health Sciences - Blantyre Malaria Project, - Center for Vaccine Development and Global Health, - Center for Vaccine Development and Global Health, - Center for Vaccine Development and Global Health, - Center for Vaccine Development and Global Health, University of Maryland, Baltimore (UMB) - School of Medicine, University of Malawi - Malawi-Liverpool-Wellcome Trust Clinical Research Programme, - Center for Vaccine Development and Global Health and University of Malawi - Malawi-Liverpool-Wellcome Trust Clinical Research Programme
Downloads 158 (472,207)

Abstract:

Loading...

Malawi, typhoid conjugate vaccine, Africa, efficacy, pediatrics

4.

Immunogenicity and Reactogenicity of a Booster Dose of a Typhoid Conjugate Vaccine (TCV) in Malawian Pre-School Children

Number of pages: 30 Posted: 28 Oct 2024
Nginache Nampota-Nkomba, Osward M. Nyirenda, Shrimati Datta, Victoria Mapemba, Priyanka D. Patel, Theresa Misiri, Felistas Mwakisighile, John Ndaferankhande, Bright Lipenga, Jennifer Oshinsky, Marcella Pasetti, Leslie P. Jamka, Melita A. Gordon, Matthew B. Laurens and Kathleen Neuzil
Kamuzu University of Health Sciences - Blantyre Malaria Project, Kamuzu University of Health Sciences - Blantyre Malaria Project, - Center for Vaccine Development and Global Health, University of Malawi - Malawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi - Malawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi - Malawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi - Malawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi - Malawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi - Malawi-Liverpool-Wellcome Trust Clinical Research Programme, - Center for Vaccine Development and Global Health, University of Maryland School of Medicine - Center for Vaccine Development and Global Health, - Center for Vaccine Development and Global Health, University of Malawi - Malawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Maryland, Baltimore (UMB) - School of Medicine and affiliation not provided to SSRN
Downloads 77 (823,616)

Abstract:

Loading...

Typhoid conjugate vaccine, Salmonella enterica, Salmonella Typhi, typhoid fever, Malawi, Africa, booster dose, immunogenicity, tetanus, enteric fever, invasive bacterial infection

5.

Safety and Immunogenicity of Co-Administration of Meningococcal Type A and Measles Rubella Vaccines with Typhoid Conjugate Vaccine in Children Aged 15-23 Months in Burkina Faso

Number of pages: 24 Posted: 22 Sep 2020
Sodiomon Sirima, Alphonse Ouedraogo, Nouhoun Barry, Mohamadou Siribie, Alfred B. Tiono, Issa Nébié, Amadou Konaté, Gloria Damoaliga Berges, Amidou Diarra, Moussa Ouedraogo, Issiaka Soulama, Alimatou Hema, Shrimati Datta, Yuanyuan Liang, Elizabeth Rotrosen, J. Kathleen Tracy, Leslie P. Jamka, Kathleen M. Neuzil and Matthew B. Laurens
Groupe de Recherche Action en Santé (GRAS), Groupe de Recherche Action en Santé (GRAS), Groupe de Recherche Action en Santé (GRAS), Groupe de Recherche Action en Santé (GRAS), Groupe de Recherche Action en Santé (GRAS), Ministry of Health, Burkina Faso - Centre National de Recherche et de Formation sur le Paludisme (CNRFP), Groupe de Recherche Action en Santé (GRAS), Groupe de Recherche Action en Santé (GRAS), Groupe de Recherche Action en Santé (GRAS), Groupe de Recherche Action en Santé (GRAS), Groupe de Recherche Action en Santé (GRAS), Groupe de Recherche Action en Santé (GRAS), - Center for Vaccine Development and Global Health, - Center for Vaccine Development and Global Health, - Center for Vaccine Development and Global Health, - Center for Vaccine Development and Global Health, - Center for Vaccine Development and Global Health, - Center for Vaccine Development and Global Health and University of Maryland, Baltimore (UMB) - School of Medicine
Downloads 56 (1,000,027)
Citation 2

Abstract:

Loading...

typhoid conjugate vaccine, meningococcal vaccines, measles rubella vaccine, sub-Saharan Africa, Burkina Faso, child, child-preschool, double-blind method, endemic diseases/prevention & control, humans, Typhoid Fever / prevention & control, Typhoid-Paratyphoid Vaccines / adverse effects, Typhoid-Paratyphoid Vaccines / immunology, Vaccines, Conjugate / adverse effects, Vaccines, Conjugate / immunology, Meningococcal Vaccines / adverse effects, Meningococcal Vaccines / immunology

6.

Impact of prior SARS-CoV-2 acquisition on binding and neutralizing antibody responses following COVID-19 vaccination: A cross-protocol analysis of individual-level data from six phase 3 clinical trials

Number of pages: 30 Posted: 10 Jan 2026
Aaron Hudson, Scott Borgetti, Anne-Marie Rick, Matthew B. Laurens, Samuel T. Robinson, Cynthia L. Gay, Lindsey Baden, Paul Goepfert, Nadine Rouphael, Hana M. El Sahly, Glenda Gray, Beatriz Grinsztejn, Magdalena Sobieszczyk, Ann R. Falsey, Yunda Huang, Holly E. Janes, Dean Follmann, Richard A. Koup, Frances Priddy, Jenny Hendriks, Kathryn Shoemaker, Lisa M. Dunkle, Guy de Bruyn, Louis Devlin, Kathleen M. Neuzil, James G. Kublin, Lawrence Corey, Stephen R. Walsh, Karen L. Kotloff and Peter B. Gilbert
Fred Hutchinson Cancer Research Center, University of Illinois Chicago, University of Pittsburgh - Department of Pediatrics, University of Maryland, Baltimore (UMB) - School of Medicine, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, University of North Carolina (UNC) at Chapel Hill - School of Medicine, Harvard University - Brigham and Women’s Hospital, University of Alabama at Birmingham - Heersink School of Medicine, Emory University, Baylor College of Medicine, South African Medical Research Council, Instituto Nacional de Infectologia Evandro Chagas, Fiocruz - Lab. De Pesquisa Clinica DST/AIDS, Columbia University - Aaron Diamond AIDS Research Center, University of Rochester, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Government of the United States of America - Biostatistics Research Branch, National Institutes of Health - Vaccine Research Center, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Novavax, Inc., Sanofi - Pennsylvania, affiliation not provided to SSRN, - Center for Vaccine Development and Global Health, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Harvard University - Brigham and Women’s Hospital, - Department of Pediatrics and Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division
Downloads 21 (1,436,435)

Abstract:

Loading...

(3-10): COVID-19, SARS-CoV-2, antibody, Vaccination, immunity, natural immunity, hybrid immunity, correlate of protection, Efficacy